Project Inform is on the steering committee for this effort to bring new HIV infections to zero, along with zero deaths and zero stigma. Watch this PBS video for more information.
The U.S. Food and Drug Administration (FDA) has issued a warning about a potentially fatal interaction between the hepatitis C drug sofosbuvir (brand name Sovaldi) and the antiarrhythmic drug amiodarone following the death of one patient and the placement of three others on a pacemaker to…Read More
A new type of drug, called a toll-like receptor 7 (TLR7) agonist, was able to activate HIV-infected CD4 cells from HIV-positive donors on antiretroviral therapy (ART), leading to the release and replication of virus, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic…Read More
A large study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle found that offering gift cards to people to reward them for getting into HIV care after testing positive or for getting their viral loads suppressed doesn’t work better than the…Read More
A defining characteristic of hepatitis C (HCV) is the fact that a person can get re-infected with the virus if she/he is exposed to it again following cure or spontaneous clearance. Additionally, a person can experience a recurrence, or “relapse”, of the virus following treatment. While…Read More
Hepatitis C (HCV) infection is a major cause of illness in people living with HIV. HCV-related liver disease is the leading non-AIDS cause of death, and people with HIV/HCV co-infection suffer from higher rates of extra-hepatic complications such and heart disease and bone fractures. With the advent…Read More
As the direct-acting antiviral era progresses, there are several options for interferon-free treatment for HCV mono-infected persons. While there are some available to HIV/HCV co-infected persons, the need for a safe and effective interferon- and ribavirin-free regimen remains. The phase 3 ALLY-2 Study, evaluating the effectiveness…Read More